公开(公告)号：EP1420815B2

公开(公告)日：2017-08-09

申请号：EP02758181.8

申请日：2002-08-20

申请人： H. Lundbeck A/S

发明人： RASMUSSEN, Peter Birk Pharmexa A/S ,  JENSEN, Martin Roland Pharmexa A/S ,  NIELSEN, Klaus Gregorius Pharmexa A/S ,  KOEFOED, Peter Pharmexa A/S ,  DEGAN, Florence Dal Pharmexa A/S

IPC分类号： A61K39/00 ,  A61K39/385 ,  C07K14/47 ,  A61P25/28

CPC分类号： A61K39/0007 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0312 ,  A61K39/385 ,  A61K45/06 ,  A61K2039/53 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/6093 ,  A61K2039/64 ,  C07K14/4711 ,  Y02A50/412

摘要： Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A²). Immunization is preferably effected by administration of analogues of autologous APP or A², said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A² which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A² and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations

摘要翻译： 公开了用于对抗以淀粉样蛋白沉积为特征的疾病的新方法。 这些方法通常依赖于针对淀粉样前体蛋白（APP）或β淀粉样蛋白（A 2）的免疫接种。 免疫优选通过施用自体APP或A 2类似物来实现，所述类似物能够诱导针对自体致淀粉状蛋白产生多肽的抗体产生。 特别优选作为免疫原的是自体A 2，其通过引入一个或几个外来免疫显性和混杂T细胞表位而被修饰。 还公开了针对APP或A 2的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和手段。 这样的方法和手段包括制备类似物和药物制剂的方法，以及核酸片段，载体，转化的细胞，多肽和药物制剂